Individuals with DNA methylation epi-signature showed significantly different metabolomic profiles when compared to the epi-signature negative individuals with small deletions sparing BRD1 and with SHANK3 mutation, indicating evidence of two clinical subtypes within PHMDS that are distinct at the molecular and phenotypic levels. This evidence concerns the gene SHANK3 and Phelan-McDermid syndrome.